Biomarin Pharmaceutical Inc (BMRN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 79.50% | 78.78% | 79.88% | 78.98% | 78.30% | 77.60% | 77.20% | 76.77% | 76.52% | 76.19% | 75.66% | 75.03% | 74.25% | 73.93% | 70.28% | 70.64% | 71.24% | 72.89% | 77.82% | 78.47% |
| Operating profit margin | 17.11% | 12.34% | 9.89% | 8.14% | 7.28% | 5.92% | 4.63% | 3.52% | 7.26% | 5.41% | 3.01% | 1.60% | -4.51% | -3.72% | -3.74% | -6.79% | -2.38% | -0.06% | 3.25% | 3.30% |
| Pretax margin | 19.14% | 14.33% | 11.65% | 9.72% | 7.95% | 6.71% | 4.95% | 3.40% | 7.26% | 5.03% | 2.96% | 1.90% | -4.12% | -3.04% | -3.74% | -7.00% | -2.69% | -0.65% | 3.26% | 3.36% |
| Net profit margin | 15.08% | 11.80% | 10.01% | 8.41% | 7.06% | 6.50% | 4.58% | 3.37% | 6.87% | 4.20% | 2.84% | 2.10% | -3.51% | 0.59% | 43.99% | 43.52% | 46.85% | 46.75% | 6.74% | 6.43% |
Biomarin Pharmaceutical Inc has shown a consistent improvement in its profitability ratios over the analyzed periods.
1. Gross Profit Margin: The company's gross profit margin started at 78.47% in March 2020 and demonstrated a positive trend, reaching 79.50% by December 2024. This indicates that Biomarin has been effectively managing its production costs and generating a higher percentage of revenue as gross profit.
2. Operating Profit Margin: Despite starting with a low margin of 3.30% in March 2020, Biomarin managed to turn around its operating profitability significantly. The company consistently improved its operating profit margin, reaching 17.11% by December 2024. This indicates efficient cost control and operational effectiveness.
3. Pretax Margin: The pretax margin also showcases a positive trend for Biomarin, starting at 3.36% in March 2020 and climbing to 19.14% by December 2024. This signifies that the company has been effectively managing its operating expenses and other costs before tax deductions.
4. Net Profit Margin: Biomarin's net profit margin reflects the company's bottom-line profitability, starting at 6.43% in March 2020 and increasing to 15.08% by December 2024. The company experienced fluctuations along the way but ultimately demonstrated an overall improvement in generating net income relative to its total revenue.
Overall, Biomarin Pharmaceutical Inc's profitability ratios indicate a positive trajectory, with improvements in all key margins over the analyzed period. This suggests the company's ability to efficiently manage costs, drive operational effectiveness, and enhance overall profitability.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 6.93% | 4.92% | 3.59% | 2.89% | 2.52% | 1.98% | 1.54% | 1.16% | 2.35% | 1.73% | 0.93% | 0.49% | -1.37% | -1.14% | -1.20% | -2.12% | -0.74% | -0.02% | 1.11% | 1.24% |
| Return on assets (ROA) | 6.11% | 4.70% | 3.63% | 2.99% | 2.45% | 2.18% | 1.52% | 1.11% | 2.22% | 1.34% | 0.88% | 0.65% | -1.07% | 0.18% | 14.11% | 13.61% | 14.60% | 13.84% | 2.31% | 2.41% |
| Return on total capital | 8.07% | 6.14% | 5.11% | 4.49% | 3.71% | 3.03% | 2.11% | 1.53% | 2.91% | 2.07% | 1.28% | 0.93% | -1.12% | -0.74% | -0.92% | -1.93% | -0.38% | 0.38% | 1.95% | 2.23% |
| Return on equity (ROE) | 7.54% | 5.95% | 4.85% | 4.05% | 3.39% | 3.00% | 2.09% | 1.54% | 3.08% | 1.84% | 1.20% | 0.90% | -1.50% | 0.25% | 19.64% | 18.98% | 20.83% | 21.02% | 3.78% | 3.52% |
Biomarin Pharmaceutical Inc's profitability ratios have shown varying trends over the past few years.
- Operating return on assets (Operating ROA): This ratio indicates the company's operating efficiency in generating profits from its assets. Biomarin's Operating ROA has fluctuated, ranging from negative percentages in some quarters to positive percentages in others. There has been a gradual improvement from negative figures to around 2-3% by the end of 2024, indicating better operational performance.
- Return on assets (ROA): ROA measures the company's ability to generate profits from its total assets. Biomarin's ROA also fluctuated over the period, starting at double digits in late 2020, then declining sharply, and gradually recovering to around 6-7% by the end of 2024. This improvement suggests a better utilization of assets to generate returns.
- Return on total capital: This ratio indicates the company's ability to generate returns from its total capital employed, including both equity and debt. Biomarin's return on total capital has shown a consistent improvement over the years, starting from negative percentages and progressively increasing to around 6-8% by the end of 2024. This indicates that the company is becoming more efficient in generating returns for all its capital providers.
- Return on equity (ROE): ROE measures how effectively the company is utilizing shareholders' equity to generate profits. Biomarin's ROE has demonstrated a similar trend to ROA, starting with high double-digit figures, experiencing a sharp decline, and then steadily increasing to around 7-8% by the end of 2024. This suggests that the company is improving its profitability in relation to shareholders' equity.
Overall, Biomarin Pharmaceutical Inc has shown improvements in its profitability ratios over the years, indicating better operational efficiency and utilization of capital to generate returns for its stakeholders.